A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy

Nozomi Niitsu, Jun Ichi Tamaru, Tadashi Yoshino, Naoya Nakamura, Shigeo Nakamura, Kohichi Ohshima, Hirokazu Nakamine, Masataka Okamoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In our previous study on nm23-H1 expression with diffuse large B-cell lymphoma (DLBCL), we found that patients with positive nm23-H1 had significantly poorer prognosis than patients with negative nm23-H1. We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab era. The subjects were 101 DLBCL patients who underwent R-CyclOBEAP (rituximab, cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, and prednisolone) therapy and in whom markers could be analyzed. We evaluated CD5, CD10, BCL2, BCL6, MUM1, and nm23-H1 expression by immunohistochemistry. Ninety-four DLBCL patients who underwent CyclOBEAP therapy were assumed as historical controls. Among DLBCL patients who underwent CyclOBEAP therapy, BCL2 positivity, MUM1 positivity, non-germinal center B-cell (non-GCB), and nm23-H1 positivity were associated with significantly shorter overall survival (OS) and progression-free survival (PFS). On the other hand, among DLBCL patients who underwent R-CyclOBEAP therapy, the 5-year OS rates of the nm23-H1-positive DLBCL (n = 32) and nm23-H1-negative DLBCL groups (n = 69) were 65% and 97%, respectively (p = 0.001), with 5-year PFS rates of 51% and 89%, respectively (p = 0.001). In the rituximab era, BCL2, MUM1, and non-GCB were not prognostic factors. We demonstrated that among patients with DLBCL who underwent R-CyclOBEAP therapy, patients with nm23-H1 expression had a significantly poorer prognosis than patients without nm23-H1 expression. These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL.

Original languageEnglish
Pages (from-to)185-192
Number of pages8
JournalAnnals of Hematology
Volume90
Issue number2
DOIs
Publication statusPublished - Feb 2011
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Bleomycin
Vincristine
Etoposide
Prednisolone
Doxorubicin
Cyclophosphamide
Therapeutics
Disease-Free Survival
B-Lymphocytes
Survival Rate
Rituximab
Immunohistochemistry
Survival

Keywords

  • BCL2
  • Diffuse large B-cell lymphoma
  • nm23
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy. / Niitsu, Nozomi; Tamaru, Jun Ichi; Yoshino, Tadashi; Nakamura, Naoya; Nakamura, Shigeo; Ohshima, Kohichi; Nakamine, Hirokazu; Okamoto, Masataka.

In: Annals of Hematology, Vol. 90, No. 2, 02.2011, p. 185-192.

Research output: Contribution to journalArticle

Niitsu, N, Tamaru, JI, Yoshino, T, Nakamura, N, Nakamura, S, Ohshima, K, Nakamine, H & Okamoto, M 2011, 'A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy', Annals of Hematology, vol. 90, no. 2, pp. 185-192. https://doi.org/10.1007/s00277-010-1060-8
Niitsu, Nozomi ; Tamaru, Jun Ichi ; Yoshino, Tadashi ; Nakamura, Naoya ; Nakamura, Shigeo ; Ohshima, Kohichi ; Nakamine, Hirokazu ; Okamoto, Masataka. / A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy. In: Annals of Hematology. 2011 ; Vol. 90, No. 2. pp. 185-192.
@article{0260693f65474acba4c887d87ae07f74,
title = "A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy",
abstract = "In our previous study on nm23-H1 expression with diffuse large B-cell lymphoma (DLBCL), we found that patients with positive nm23-H1 had significantly poorer prognosis than patients with negative nm23-H1. We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab era. The subjects were 101 DLBCL patients who underwent R-CyclOBEAP (rituximab, cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, and prednisolone) therapy and in whom markers could be analyzed. We evaluated CD5, CD10, BCL2, BCL6, MUM1, and nm23-H1 expression by immunohistochemistry. Ninety-four DLBCL patients who underwent CyclOBEAP therapy were assumed as historical controls. Among DLBCL patients who underwent CyclOBEAP therapy, BCL2 positivity, MUM1 positivity, non-germinal center B-cell (non-GCB), and nm23-H1 positivity were associated with significantly shorter overall survival (OS) and progression-free survival (PFS). On the other hand, among DLBCL patients who underwent R-CyclOBEAP therapy, the 5-year OS rates of the nm23-H1-positive DLBCL (n = 32) and nm23-H1-negative DLBCL groups (n = 69) were 65{\%} and 97{\%}, respectively (p = 0.001), with 5-year PFS rates of 51{\%} and 89{\%}, respectively (p = 0.001). In the rituximab era, BCL2, MUM1, and non-GCB were not prognostic factors. We demonstrated that among patients with DLBCL who underwent R-CyclOBEAP therapy, patients with nm23-H1 expression had a significantly poorer prognosis than patients without nm23-H1 expression. These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL.",
keywords = "BCL2, Diffuse large B-cell lymphoma, nm23, Rituximab",
author = "Nozomi Niitsu and Tamaru, {Jun Ichi} and Tadashi Yoshino and Naoya Nakamura and Shigeo Nakamura and Kohichi Ohshima and Hirokazu Nakamine and Masataka Okamoto",
year = "2011",
month = "2",
doi = "10.1007/s00277-010-1060-8",
language = "English",
volume = "90",
pages = "185--192",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy

AU - Niitsu, Nozomi

AU - Tamaru, Jun Ichi

AU - Yoshino, Tadashi

AU - Nakamura, Naoya

AU - Nakamura, Shigeo

AU - Ohshima, Kohichi

AU - Nakamine, Hirokazu

AU - Okamoto, Masataka

PY - 2011/2

Y1 - 2011/2

N2 - In our previous study on nm23-H1 expression with diffuse large B-cell lymphoma (DLBCL), we found that patients with positive nm23-H1 had significantly poorer prognosis than patients with negative nm23-H1. We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab era. The subjects were 101 DLBCL patients who underwent R-CyclOBEAP (rituximab, cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, and prednisolone) therapy and in whom markers could be analyzed. We evaluated CD5, CD10, BCL2, BCL6, MUM1, and nm23-H1 expression by immunohistochemistry. Ninety-four DLBCL patients who underwent CyclOBEAP therapy were assumed as historical controls. Among DLBCL patients who underwent CyclOBEAP therapy, BCL2 positivity, MUM1 positivity, non-germinal center B-cell (non-GCB), and nm23-H1 positivity were associated with significantly shorter overall survival (OS) and progression-free survival (PFS). On the other hand, among DLBCL patients who underwent R-CyclOBEAP therapy, the 5-year OS rates of the nm23-H1-positive DLBCL (n = 32) and nm23-H1-negative DLBCL groups (n = 69) were 65% and 97%, respectively (p = 0.001), with 5-year PFS rates of 51% and 89%, respectively (p = 0.001). In the rituximab era, BCL2, MUM1, and non-GCB were not prognostic factors. We demonstrated that among patients with DLBCL who underwent R-CyclOBEAP therapy, patients with nm23-H1 expression had a significantly poorer prognosis than patients without nm23-H1 expression. These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL.

AB - In our previous study on nm23-H1 expression with diffuse large B-cell lymphoma (DLBCL), we found that patients with positive nm23-H1 had significantly poorer prognosis than patients with negative nm23-H1. We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab era. The subjects were 101 DLBCL patients who underwent R-CyclOBEAP (rituximab, cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, and prednisolone) therapy and in whom markers could be analyzed. We evaluated CD5, CD10, BCL2, BCL6, MUM1, and nm23-H1 expression by immunohistochemistry. Ninety-four DLBCL patients who underwent CyclOBEAP therapy were assumed as historical controls. Among DLBCL patients who underwent CyclOBEAP therapy, BCL2 positivity, MUM1 positivity, non-germinal center B-cell (non-GCB), and nm23-H1 positivity were associated with significantly shorter overall survival (OS) and progression-free survival (PFS). On the other hand, among DLBCL patients who underwent R-CyclOBEAP therapy, the 5-year OS rates of the nm23-H1-positive DLBCL (n = 32) and nm23-H1-negative DLBCL groups (n = 69) were 65% and 97%, respectively (p = 0.001), with 5-year PFS rates of 51% and 89%, respectively (p = 0.001). In the rituximab era, BCL2, MUM1, and non-GCB were not prognostic factors. We demonstrated that among patients with DLBCL who underwent R-CyclOBEAP therapy, patients with nm23-H1 expression had a significantly poorer prognosis than patients without nm23-H1 expression. These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL.

KW - BCL2

KW - Diffuse large B-cell lymphoma

KW - nm23

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=78751566627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751566627&partnerID=8YFLogxK

U2 - 10.1007/s00277-010-1060-8

DO - 10.1007/s00277-010-1060-8

M3 - Article

VL - 90

SP - 185

EP - 192

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 2

ER -